Related Experiment Video
Updated: Jul 13, 2026
Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
Concerning the anti-arthritic action of cetyl myristoleate in rats: an interim report
1Department of Medicine, University of Queensland, 4102, Brisbane, Australia.
Abstract:
The proposed arthro-preventive action of cetyl myristoleate, an OTC product sold as a nutritional supplement, could not be confirmed, using an almost identical bioassay (adjuvant-induced polyarthritis in rats) as that described in the original report (Diehl and May, 1994) with the same, and 3 other, dosing schedules.
Insights
Cetyl myristoleate, a nutritional supplement, did not prevent arthritis in rats during this study. Researchers could not confirm the proposed joint-protective effects in their bioassay.
Area of Science:
- Immunology and Pharmacology
- Rheumatology
- Nutritional Science
Background:
- Cetyl myristoleate is an over-the-counter (OTC) product marketed as a nutritional supplement.
- Previous research suggested potential arthro-preventive (joint-protective) properties of cetyl myristoleate.
Purpose of the Study:
- To investigate and confirm the proposed joint-protective action of cetyl myristoleate.
- To evaluate the efficacy of cetyl myristoleate in a validated animal model of arthritis.
Main Methods:
- An adjuvant-induced polyarthritis bioassay in rats was employed, closely mirroring a previously published methodology.
- Multiple dosing schedules, including the original and three additional regimens, were tested.
Main Results:
- The study failed to confirm the proposed arthro-preventive action of cetyl myristoleate.
- Results were consistent across all tested dosing schedules.
Conclusions:
- The joint-protective effects of cetyl myristoleate could not be substantiated under the experimental conditions used.
- Further research may be needed to clarify the role, if any, of cetyl myristoleate in joint health.
